Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Other Events

Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Other Events
Item 8.01. Other Events.

Story continues below

On February 15, 2018, Argos Therapeutics, Inc. (the “Company”) received formal notice from Nasdaq indicating that the Company has evidenced full compliance with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. to the Nasdaq Hearings Panel (the “Panel”) decision dated January 17, 2018, the Company was required to evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days by February 2, 2018. As of the close of business on February 15, 2018, the Company evidenced a minimum closing bid price of $1.00 per share for 20 consecutive trading days.

The Panel’s decision also requires the Company to publicly disclose, on or before April 24, 2018, that it has stockholders’ equity in excess of $2.5 million and to demonstrate the Company’s ability to sustain compliance with the minimum stockholders’ equity requirement through the end of fiscal 2018, among other actions, as well as otherwise continue to meet the requirements for continued listing on The Nasdaq Capital Market.

About Argos Therapeutics, Inc. (NASDAQ:ARGS)

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

An ad to help with our costs